Medicare Coverage For Leqembi: Timeline For Reconsideration Of Restrictions
Executive Summary
After getting a formal request for Medicare to reconsider coverage for Eisai’s new drug and other mAbs, CMS must decide by mid February whether to undertake the process. The formal timeline for reconsideration runs six to 12 months; past reviews have taken around nine months.
You may also be interested in...
CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen
Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.
Medicare Coverage For Alzheimer’s Drugs: CMS Declines To Revise Restrictions For Class
Medicare coverage restrictions are more likely to be reconsidered on a case-by-case basis as drugs in the class obtain traditional US Food and Drug Administration approvals in the coming months.
Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer’s Drug Leqembi
Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.